|
|
Home > Healthcare > Pharmaceutical > General Pharmaceutical
Latvia Pharmaceuticals and Healthcare Report Q3 2009
|
|
- Executive Summary
- SWOT Analysis
- Latvia Pharmaceuticals And Healthcare Industry SWOT
- Latvia Political SWOT
- Latvia Economic SWOT
- Latvia Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Table: Regional Pharma Business Environment Ratings
- Limits of Potential Returns
- Risks to Realisation of Returns
- Latvia - Market Summary
- Regulatory Regime
- Regional Collaboration
- Corruption
- Intellectual Property Developments
- Pricing Regime
- Reimbursement Regime
- Industry Developments
- Epidemiology
- Healthcare Sector
- Healthcare Provision
- Pharmaceutical Industry
- Recent Pharmaceutical Company Developments
- Pharmaceutical Wholesale
- And Distribution
- Pharmaceutical Retail
- Table: Latvia Pharmacies And Pharmacy Market Ratios, 2004-2009
- Biotechnology
- Clinical Trials
- Medical Devices
- Industry Forecast Scenario
- Overall Market Forecast
- Table: Latvia - Drug Expenditure Indicators, Historical Data And Forecasts, 2003-2013
- Key Growth Factors - Industry
- Table: Latvia - Health Expenditure Indicators, Historical Data And Forecasts, 2003-2013
- Key Growth Factors - Macroeconomic
- Table: Latvia - Economic Activity, 2006 - 2013
- Prescription Market Forecast
- Table: Latvia - Prescription Market Indicators, Historical Data And Forecasts (LVLmn unless otherwise stated)
- Patented Market Forecast
- Table: Latvia - Patented Drug Market Indicators, Historical Data And Forecasts, 2003-2013
- Generics Market Forecast
- Table: Latvia - Generics Market Indicators, Historical Data And Forecasts, 2003-2013
- OTC Market Forecast
- Table: Latvia - OTC Market Indicators, Historical Data And Forecasts (LVLmn unless otherwise stated), 2003-2013
- Export/Import Forecasts
- Table: Latvia - Pharmaceutical Trade Indicators, Historical Data And Forecasts, 2003-2013 (US$mn)
- Other Healthcare Data Forecasts
- Table: Latvia - Other Healthcare Indicators, Historical Data And Forecasts, 2003-2013
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Company Monitor
- Multinational Company Profiles
- Pfizer
- GlaxoSmithKline
- Sanofi-Aventis
- Novartis
- Merck & Co
- Indigenous Company Profiles
- Grindeks (includes Tallinn Pharmaceutical Plant)
- Olainfarm
- Country Snapshot: Latvia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
|
Similar Products
• United States Type 2 Diabetes Market
Published Nov 2009 by Intellent
• Snapshots Poland Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Venezuela Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Spain Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots South Africa Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Snapshots Hungary Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Kenya Pharmaceuticals and Healthcare Report Q1 2010
Published Nov 2009 by Business Monitor International
• Company Financials: Bayer AG
Published Nov 2009 by Datamonitor
• Merck & Co. Performance, Products, Pipeline and Potential
Published Nov 2009 by Espicom Healthcare Intelligence
|
|
|
|
0 items
